Cardiac Resynchronization Therapy (CRT)-Narrow-dp/Dt-Study

CRT in Patients With Narrow QRS, Echodesynchronisation and LV dp/Dt-Response With Pressure Wire

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00821938

Acronym

CRT-Narrow

Enrollment

Registered

2009-01-14

Start date

2008-11-30

Completion date

2016-07-31

Last updated

2025-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Narrow QRS, CRT

Brief summary

Goal is to examine the efficy of Cardiac Resynchronization Therapy in heart failure patients with narrow QRS complex and optimized medical treatment but echocardiographic desynchronization detection as well as the positve increase of the intraoperative pressureincreasespeed in reverse remodelling and a secondary improvement of functional parameters

Interventions

PROCEDURELV dp/dt pressure measurement

Assessment of response to bi-ventricular pacing. Responder-arm, will be permanently paced bi-ventricularly

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* EF \< 35% * CHD or dilate cardiomyopathy * sinus rhythm * NYHA III (or IV but stable recompenstated) * QRS \< 120 ms 2-3 of the following: * LV-fillingtime \< 40% of the cyclelength * TDI septal-lateral (LV basal) \> 60ms * 2D-Strain-Score \> 9 points

Exclusion criteria

* tricuspid or artificial valve * AV block II or III or PQ time \> 250ms * revasculisation or condition after cardiac surgery \< 3 months * myocardial infarction or bypass OP \< 3 months * hytertrphic obstructive cardiomyopathy, constrictive pericarditis * intravenous catecholamines because of HF * manifeste hyperthyreoses * kidney failure (creatine \>2,5 mg/dl) * no written informed consent * no compliance * participation in another study * life expectancy \< 1 year * patients \< 18 years * pragnancy or no safe contraception

Design outcomes

Primary

Measure	Time frame
Indexed left ventricular volume	12 months

Secondary

Measure	Time frame
NYHA-class, 6 minute hallwalk, QOL, BNP-level, echo-criteria	12 months

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026